Facts
as of Nov 18, 2026
We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases. Learn more about Sarepta.
It is hiring: 8 open roles, 7 of them posted in the last 30 days.
- Legal name
- Sarepta Therapeutics, Inc.
- Headquarters
- Cambridge, United States
- Employees
- 501-1000estimated range
- Register numbers
- EIN 930797222
As of Nov 18, 2026, Alion lists 8 open roles at Sarepta. Sarepta is headquartered in Cambridge, United States. The median pay stated in its open roles is $201k, across 8 postings that state pay.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Legal entity active
Sarepta Therapeutics, Inc.
Not checked
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Hiring at full speed: most open roles are fresh.
Biotech is the largest family, 32 of open roles.
7Posted in 30 days78% of open roles are fresh
0%Remote roles0 of 9
11Hiring offices
Can they hire you from United States?by your location
Likely
20 open roles are in your country: you apply locally, no move needed.
United States20On site
Remote, from elsewhere0Rare
No posting offers visa sponsorship. Remote roles: 0.
Time to fillmedian days to close a role
Sarepta26 days
Market, same roles31 days
Alion signals0-100
Demand9
Pay35
Your chance39
How badly they need people, whether they pay, how realistic getting in is.
Open roles over time−100%
Sep 28This week
Open roles a week: 6 then, 0 now
Where the openings areshare of open roles · trend
Biotech32▲
Marketing11▲
Sales11▼
Operations11▲
QA5▼
Leadership5▼
Degree asked
Bachelor's Degree 100%
4 postings state a degree.
Benefits named in postingsshare of open roles
Equity788%
Continuous learning225%
Contract type
Full-Time 8
Visa sponsorship: none statedRelocation: none stated
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family
What its postings pay, by level.
$201kMedianmarket estimate $189k
$145k – $217kTypical rangeUSD a year
$232kHighest paying roleDirector, Global Pharmacovigilance Operations Lead
Pay by levelmiddle half of stated pay, median marked · dashed: market median $189k
Senior3$170k$145k – $170k
Head+3$201k
$0$63k$125k$188k$250k
People cost
Sarepta filed a median H-1B wage of $170k in 2026.
1,362People on payrollPERM filings, 2026Source ↗ $170kMedian H-1B wage, 20267 casesSource ↗ $92k–$197kH-1B wage range7 positions
Median H-1B wage by role, 2026scale to $197k
Sr. Principal Engineer, Manufacturing Sciences & Technology · 2$151k
QC Analyst · 1$92k
Associate Director, IT Validation · 1$177k
Director, Quality Control · 1$191k
Senior Manager, CMC Regulatory Affairs · 1$144k
Source: the pay stated in the company's postings, normalised to USD a year
Named in the work visa registers of United States.
8 ▼ 68%H-1B filings in 12 months
4Green card filings
$133kMedian offered salary
In the register as Sarepta Therapeutics, Inc., Cambridge, MA (+1 more)
Other sponsors in the same field
Footprint
Hiring in 11 cities in 1 country.
11Cities
1Countries
CambridgeBusiest site
Source: office addresses in postings and company registers
Ranked #6 by open roles among its 11 closest peers.
Source: Alion's similar-companies engine (industry segments, technologies, headquarters country, size)
Financials
Revenue of $2.2B in 2025. +15.6% on the year before. Net income −$713.4M.
$2.2BRevenue2025 · +15.6%
−$713.4MNet income2025 · −403.3%
Revenue by yearas filed, with the net income
2025$2.2Bnet income −$713.4M
2024$1.9Bnet income $235.2M
2023$1.2Bnet income −$536M
2022$933Mnet income −$703.5M
2021$701.9Mnet income −$418.8M
2020$540.1Mnet income −$554.1M
2019$380.8Mnet income −$715.1M
2018$301Mnet income −$361.9M
Sources: SEC
Money
Sarepta returned $25M to shareholders in fiscal 2025 and paid $37.6M of income tax.
$37.6MIncome taxes paidFY2025
$25MDividends and buybacksFY2025
$102MCapital expenditureFY2025
| FY2023 | FY2024 | FY2025 |
| Income taxes paid | $15.1M | $22.6M | $37.6M |
| Shares bought back | – | – | $25M |
| Capital expenditure | $76.1M | $137M | $102M |
| Stock-based compensation | $182.5M | $184.3M | $123.4M |
Taxes
Income taxes paid are in the table of its filings above.
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Public record
Sarepta: $1.2M of EU lobbying in 2025, 13 federal court cases.
Influence
Employees' political contributions, 2026 cycle
671 contributions · their own money, not the company's; names not shown ·
fec.gov ↗$134k
Patents
Published US applications
65
US federal cases naming it as a party
Aug 2019 – Jul 2024 · 10 as defendant · 7 closed
Most common: 830 Patent 5, 830 Patent Infringement (Fed. Qst.) 1, 850 Securities/Commodities 1, Contract: Other 1
13
Each line links its register: the agency's page, the EU Transparency Register, the FEC, the USPTO, CourtListener.
Technologies named in job postings at Sarepta over the last 12 months, by layer, with the share of postings for each.
12Technologies in use
7Postings analysed
55/100Stack modernity
Sign in to see how your skills match this stackSign In
Source: the technologies named in the company's postings and on its site
Milestones
Each milestone is dated by its source: registers, filings, the press
Newsroom
Oct 22026
News · BioSpace
Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented…
Sep 302026
News · Sarepta Therapeutics stock falls 1.28 percent as DMD data land
Sarepta Therapeutics stock posted Q2 revenue of USD 401.25 million and EPS of USD 0.64 on August 5, 2026. ELEVIDYS data covered older patients at the September 30 congress.
Sep 302026
News · marketscreener.com
Sep 302026
News · marketscreener.com
Sep 262026
News · YahooFinance
In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta ag…
Sources: the outlets named on each headline, each story once